Use of rifampicin and graft removal are associated with better outcomes in prosthetic vascular graft infection.
Rifampicin
Staphylococcus aureus
Vascular prosthesis infection
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
16
06
2020
accepted:
30
10
2020
pubmed:
4
1
2021
medline:
3
8
2021
entrez:
3
1
2021
Statut:
ppublish
Résumé
Prosthetic vascular graft infection (PVGI) is a very severe disease. We aimed to determine the factors associated with treatment failure. Patients admitted to two University Hospitals with PVGI were included in this retrospective study. PVGI was classified as possible, probable or proven according to an original set of diagnostic criteria. We defined treatment failure if one of the following events occurred within the first year after PVGI diagnosis: death and infection recurrence due to the same or another pathogen. One hundred and twelve patients were diagnosed with possible (n = 26), probable (n = 22) and proven (n = 64) PVGI. Bacterial documentation was obtained for 81% of patients. The most frequently identified pathogen was Staphylococcus aureus (n = 39). Surgery was performed in 96 patients (86%). Antibiotics were administered for more than 6 weeks in 41% of patients. Treatment failure occurred in 30 patients (27.5%). The factors associated with a lower probability of treatment failure were total removal of the infected graft (OR = 0.2, 95% CI [0.1-0.6]), rifampicin administration (OR = 0.3 [0.1-0.9]) and possible PVGI according to the GRIP criteria (OR = 0.3 [0.1-0.9]). Treatment failure occurred in 27.5% of patients with PVGI. Total removal of the infected graft and rifampicin administration were associated with better outcomes.
Identifiants
pubmed: 33389709
doi: 10.1007/s15010-020-01551-z
pii: 10.1007/s15010-020-01551-z
doi:
Substances chimiques
Anti-Bacterial Agents
0
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-133Références
O’Connor S, Andrew P, Batt M, Becquemin JP. A systematic review and meta-analysis of treatments for aortic graft infection. J Vasc Surg. 2006;44:38-45 e8.
doi: 10.1016/j.jvs.2006.02.053
Seeger JM. Management of patients with prosthetic vascular graft infection. Am Surg. 2000;66:166–77.
pubmed: 10695748
Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422–9.
doi: 10.1056/NEJMra035415
Anagnostopoulos A, Ledergerber B, Kuster SP, Scherrer AU, Näf B, Greiner MA, et al. Inadequate perioperative prophylaxis and postsurgical complications after graft implantation are important risk factors for subsequent vascular graft infections: prospective results from the vascular graft infection cohort study. Clin Infect Dis. 2019;69:621–30.
doi: 10.1093/cid/ciy956
Erb S, Sidler JA, Elzi L, Gurke L, Battegay M, Widmer AF, et al. Surgical and antimicrobial treatment of prosthetic vascular graft infections at different surgical sites: a retrospective study of treatment outcomes. PLoS ONE. 2014;9:e112947.
doi: 10.1371/journal.pone.0112947
Elens M, Dusoruth M, Astarci P, Mastrobuoni S, Bosiers MJ, Nardella J, et al. Management and outcome of prosthetic vascular graft infections: a single center experience. Vasc Endovasc Surg. 2018;52(3):181–7. https://doi.org/10.1177//1538574418754453 .
doi: 10.1177//1538574418754453
Saleem BR, Meerwaldt R, Tielliu IFJ, Verhoeven ELG, van den Dungen JJAM, Zeebregts CJ. Conservative treatment of vascular prosthetic graft infection is associated with high mortality. Am J Surg. 2010;200:47–52.
doi: 10.1016/j.amjsurg.2009.05.018
Chiesa R, Astore D, Frigerio S, Garriboli L, Piccolo G, Castellano R, et al. Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir Belg. 2002;102:238–47.
doi: 10.1080/00015458.2002.11679305
O’Hara PJ, Hertzer NR, Beven EG, Krajewski LP. Surgical management of infected abdominal aortic grafts: review of a 25-year experience. J Vasc Surg. 1986;3:725–31.
doi: 10.1016/0741-5214(86)90036-4
Leroy O, Meybeck A, Sarraz-Bournet B, d’Elia P, Legout L. Vascular graft infections. Curr Opin Infect Dis. 2012;25:154–8.
doi: 10.1097/QCO.0b013e3283501853
Revest M, Camou F, Senneville E, Caillon J, Laurent F, Calvet B, et al. Medical treatment of prosthetic vascular graft infections: review of the literature and proposals of a Working Group. Int J Antimicrob Agents. 2015;46:254–65.
doi: 10.1016/j.ijantimicag.2015.04.014
FitzGerald SF, Kelly C, Humphreys H. Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother. 2005;56:996–9.
doi: 10.1093/jac/dki382
Batt M, Feugier P, Camou F, Coffy A, Senneville E, Caillon J, et al. A meta-analysis of outcomes after in situ reconstructions for aortic graft infection. Angiology. 2018;69(5):370–9. https://doi.org/10.1177//0003319717710114 .
doi: 10.1177//0003319717710114
pubmed: 28578619
Senneville E. Diagnostic des infections sur prothèses vasculaires [internet]. Clermont-Ferrand; 2013 [cited 2019 Jan 27]. https://www.infectiologie.com/UserFiles/File/medias/JNI/JNI13/2013-JNI-Diag-IPV-senneville.pdf .
R Core Team. R: a language and environment for statistical computing [internet]. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/ .
Lyons OTA, Baguneid M, Barwick TD, Bell RE, Foster N, Homer-Vanniasinkam S, et al. Diagnosis of aortic graft infection: a case definition by the management of aortic graft infection collaboration (MAGIC). Eur J Vasc Endovasc Surg. 2016;52:758–63.
doi: 10.1016/j.ejvs.2016.09.007
Legout L, Delia P, Sarraz-Bournet B, Rouyer C, Massongo M, Valette M, et al. Factors predictive of treatment failure in staphylococcal prosthetic vascular graft infections: a prospective observational cohort study: impact of rifampin. BMC Infect Dis. 2014;14:228.
doi: 10.1186/1471-2334-14-228
Legout L, Sarraz-Bournet B, D’Elia PV, Devos P, Pasquet A, Caillaux M, et al. Characteristics and prognosis in patients with prosthetic vascular graft infection: a prospective observational cohort study. Clin Microbiol Infect. 2012;18:352–8.
doi: 10.1111/j.1469-0691.2011.03618.x
Senneville E, Joulie D, Legout L, Valette M, Dezèque H, Beltrand E, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcusaureus. Clin Infect Dis. 2011;53:334–40.
doi: 10.1093/cid/cir402
Boudjemaa R, Steenkeste K, Jacqueline C, Briandet R, Caillon J, Boutoille D, et al. Live intramacrophagic Staphylococcus aureus as a potential cause of antibiotic therapy failure: observations in an in vivo mouse model of prosthetic vascular material infections. J Antimicrob Chemother. 2018;73:2418–21.
doi: 10.1093/jac/dky205
Zheng Z, Stewart PS. Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother. 2002;46:900–3.
doi: 10.1128/AAC.46.3.900-903.2002
Boudjemaa R, Briandet R, Revest M, Jacqueline C, Caillon J, Fontaine-Aupart M-P, et al. New insight into daptomycin bioavailability and localization in Staphylococcus aureus biofilms by dynamic fluorescence imaging. Antimicrob Agents Chemother. 2016;60:4983–90.
doi: 10.1128/AAC.00735-16
Legout L, D’Elia PV, Sarraz-Bournet B, Haulon S, Meybeck A, Senneville E, et al. Diagnosis and management of prosthetic vascular graft infections. Med Mal Infect. 2012;42:102–9.
doi: 10.1016/j.medmal.2012.01.003
Maze MJ, Laws P, Buckenham T, Pithie A, Gallagher K, Metcalf S, et al. Outcomes of infected abdominal aortic grafts managed with antimicrobial therapy and graft retention in an unselected cohort. Eur J Vasc Endovasc Surg. 2013;45:373–80.
doi: 10.1016/j.ejvs.2013.01.019
Calligaro KD, Veith FJ, Schwartz ML, Goldsmith J, Savarese RP, Dougherty MJ, et al. Selective preservation of infected prosthetic arterial grafts. Analysis of a 20-year experience with 120 extracavitary-infected grafts. Ann Surg. 1994;220:461–71.
doi: 10.1097/00000658-199410000-00005